Abstract A023: The clinical utility of the modified Glasgow Prognostic Score in patients undergoing potentially curative colorectal cancer resection

Abstract

Abstract The aim of the present study was to examine the clinical utility of assessment of the systemic inflammatory response, using the modified Glasgow Prognostic Score (mGPS), in combination with TNM stage in 1000 consecutive patients undergoing potentially curative colorectal cancer resection in a single institution. An mGPS of 0 (CRP<10mg/L), 1 (CRP>10mg/L/ albumin<35g/L) and 2 (CRP>10mg/L/ albumin<35g/L) was observed in 63%, 21% and 16% of patients respectively. The mGPS was associated with reduced cancer-specific survival (P<0.01), independent of TNM stage; the combination of TNM stage and mGPS stratified five-year survival from 97% (TNM I, mGPS=0) to 32% (TNM III, mGPS=2) (P<0.001). Furthermore, in patients undergoing elective resection of TNM III colon cancer, mGPS stratified survival of patients who received adjuvant chemotherapy from 91% (mGPS=0) to 56% (mGPS=2) (P=0.001). Indeed, the mGPS is routinely available and, in combination with TNM-based staging, provides additional prognostic information following potentially curative colorectal cancer resection. Citation Format: James H. Park, Campbell SD Roxburgh, Paul G. Horgan, Donald C. McMillan. The clinical utility of the modified Glasgow Prognostic Score in patients undergoing potentially curative colorectal cancer resection. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A023.